- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Recently Accepted Articles ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 239257, 10 pages
An Inherited Heteroplasmic Mutation in Mitochondrial Gene COI in a Patient with Prostate Cancer Alters Reactive Oxygen, Reactive Nitrogen and Proliferation
1Department of Urology, School of Medicine, Emory University, 1365 Clifton Rd. Building B, Atlanta, GA 30322, USA
2Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA
3Center for Molecular and Mitochondrial Medicine and Genetics (MAMMAG), University of California Irvine, Irvine, CA 92697, USA
4Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA 30322, USA
5Department of Urology, The Atlanta VA Medical Center, Decatur, GA 30033, USA
6Center for Mitochondrial and Epigenomic Medicine, Children's Hospital of Philadelphia and Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
7Department of Pathology, University of Pennsylvania, Philadelphia, PA 19104, USA
Received 6 June 2012; Revised 8 August 2012; Accepted 9 August 2012
Academic Editor: Gurmit Singh
Copyright © 2013 Rebecca S. Arnold et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- D. C. Wallace, “A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine,” Annual Review of Genetics, vol. 39, pp. 359–407, 2005.
- S. I. Zhadanov, E. Y. Grechanina, Y. B. Grechanina et al., “Fatal manifestation of a de novo ND5 mutation: insights into the pathogenetic mechanisms of mtDNA ND5 gene defects,” Mitochondrion, vol. 7, no. 4, pp. 260–266, 2007.
- W. Fan, K. G. Waymire, N. Narula et al., “A mouse model of mitochondrial disease reveals germline selection against severe mtDNA mutations,” Science, vol. 319, no. 5865, pp. 958–962, 2008.
- M. Gómez-Zaera, J. Abril, L. González et al., “Identification of somatic and germline mitochondrial DNA sequence variants in prostate cancer patients,” Mutation Research, vol. 595, no. 1-2, pp. 42–51, 2006.
- J. A. Petros, A. K. Baumann, E. Ruiz-Pesini et al., “MtDNA mutations increase tumorigenicity in prostate cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 3, pp. 719–724, 2005.
- A. M. Ray, K. A. Zuhlke, A. M. Levin, J. A. Douglas, K. A. Cooney, and J. A. Petros, “Sequence variation in the mitochondrial gene cytochrome c oxidase subunit I and prostate cancer in African American men,” Prostate, vol. 69, no. 9, pp. 956–960, 2009.
- C. Jerónimo, S. Nomoto, O. L. Caballero et al., “Mitochondrial mutations in early stage prostate cancer and bodily fluids,” Oncogene, vol. 20, no. 37, pp. 5195–5198, 2001.
- M. Higuchi, T. Kudo, S. Suzuki et al., “Mitochondrial DNA determines androgen dependence in prostate cancer cell lines,” Oncogene, vol. 25, no. 10, pp. 1437–1445, 2006.
- T. Mizumachi, L. Muskhelishvili, A. Naito et al., “Increased distributional variance of mitochondrial DNA content associated with prostate cancer cells as compared with normal prostate cells,” Prostate, vol. 68, no. 4, pp. 408–417, 2008.
- J. Maki, K. Robinson, B. Reguly et al., “Mitochondrial genome deletion aids in the identification of false- and true-negative prostate needle core biopsy specimens,” American Journal of Clinical Pathology, vol. 129, no. 1, pp. 57–66, 2008.
- B. A. Aldridge, S. D. Lim, A. K. Baumann et al., “Automated sequencing of complete mitochondrial genomes from laser-capture microdissected samples,” BioTechniques, vol. 35, no. 3, pp. 606–612, 2003.
- J. M. Seigneurin, B. Guilbert, M. J. Bourgeat, and S. Avrameas, “Polyspecific natural antibodies and autoantibodies secreted by human lymphocytes immortalized with Epstein-Barr virus,” Blood, vol. 71, no. 3, pp. 581–585, 1988.
- L. C. Costello, Z. Guan, B. Kukoyi, P. Feng, and R. B. Franklin, “Terminal oxidation and the effects of zinc in prostate versus liver mitochondria,” Mitochondrion, vol. 4, no. 4, pp. 331–338, 2004.
- M. M. Bradford, “A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding,” Analytical Biochemistry, vol. 72, no. 1-2, pp. 248–254, 1976.
- D. Hammond-McKibben, P. Lake, J. Zhang, N. Tart-Risher, R. Hugo, and M. Weetall, “A high-capacity quantitative mouse model of drug-mediated immunosuppression based on rejection of an allogeneic subcutaneous tumor,” Journal of Pharmacology and Experimental Therapeutics, vol. 297, no. 3, pp. 1144–1151, 2001.
- M. Ingman and U. Gyllensten, “mtDB: human mitochondrial genome database, a resource for population genetics and medical sciences,” Nucleic Acids Research, vol. 34, pp. D749–751, 2006.
- J. F. Turrens, “Mitochondrial formation of reactive oxygen species,” Journal of Physiology, vol. 552, no. 2, pp. 335–344, 2003.
- K. Polyak, Y. Li, H. Zhu et al., “Somatic mutations of the mitochondrial genome in human colorectal tumours,” Nature Genetics, vol. 20, no. 3, pp. 291–293, 1998.
- T. A. Scott, R. Arnold, and J. A. Petros, “Mitochondrial cytochrome c osidase subunit 1 sequence variation in prostate cancer,” Scientifica, vol. 2012, Article ID 701810, 7 pages, 2012.
- Y. Zhang, Y. Du, W. Le, K. Wang, N. Kieffer, and J. Zhang, “Redox control of the survival of healthy and diseased cells,” Antioxid Redox Signal, vol. 15, no. 11, pp. 2867–2908, 2011.
- D. Ziech, R. Franco, A. Pappa, and M. I. Panayiotidis, “Reactive Oxygen Species (ROS)—induced genetic and epigenetic alterations in human carcinogenesis,” Mutation Research, vol. 711, no. 1-2, pp. 167–173, 2011.
- G. Gupta-Elera, A. R. Garrett, R. A. Robison, and K. L. O'Neill, “The role of oxidative stress in prostate cancer,” European Journal of Cancer Prevention, vol. 21, no. 2, pp. 155–162, 2012.
- T. P. Szatrowski and C. F. Nathan, “Production of large amounts of hydrogen peroxide by human tumor cells,” Cancer Research, vol. 51, no. 3, pp. 794–798, 1991.
- H. Wiseman and B. Halliwell, “Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer,” Biochemical Journal, vol. 313, pp. 17–29, 1996.
- O. Warburg, “On respiratory impairment in cancer cells,” Science, vol. 124, no. 3215, pp. 269–270, 1956.
- C. S. Cobbs, J. E. Brenman, K. D. Aldape, D. S. Bredt, and M. A. Israel, “Expression of nitric oxide synthase in human central nervous system tumors,” Cancer Research, vol. 55, no. 4, pp. 727–730, 1995.
- S. Ambs, W. G. Merriam, W. P. Bennett et al., “Frequent nitric oxide synthase-2 expression in human colon adenomas: implication for tumor angiogenesis and colon cancer progression,” Cancer Research, vol. 58, no. 2, pp. 334–341, 1998.
- S. Ekmekcioglu, J. Ellerhorst, C. M. Smid et al., “Inducible nitric oxide synthase and nitrotyrosine in human metastatic melanoma tumors correlate with poor survival,” Clinical Cancer Research, vol. 6, no. 12, pp. 4768–4775, 2000.
- S. H. Aaltomaa, P. K. Lipponen, and V. M. Kosma, “Inducible nitric oxide synthase (iNOS) expression and its prognostic value in prostate cancer,” Anticancer Research, vol. 21, no. 4B, pp. 3101–3106, 2001.
- P. K. Lala and C. Chakraborty, “Role of nitric oxide in carcinogenesis and tumour progression,” The Lancet Oncology, vol. 2, no. 3, pp. 149–156, 2001.
- D. Massi, A. Franchi, I. Sardi et al., “Inducible nitric oxide synthase expression in benign and malignant cutaneous melanocytic lesions,” The Journal of Pathology, vol. 194, no. 2, pp. 194–200, 2001.
- A. S. Bulut, E. Erden, S. D. Sak, H. Doruk, N. Kursun, and D. Dincol, “Significance of inducible nitric oxide synthase expression in benign and malignant breast epithelium: an immunohistochemical study of 151 cases,” Virchows Archiv, vol. 447, no. 1, pp. 24–30, 2005.
- S. Singh and A. K. Gupta, “Nitric oxide: role in tumour biology and iNOS/NO-based anticancer therapies,” Cancer Chemotherapy and Pharmacology, vol. 67, no. 6, pp. 1211–1224, 2011.
- K. Ishikawa, K. Takenaga, M. Akimoto et al., “ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis,” Science, vol. 320, no. 5876, pp. 661–664, 2008.